Pfizer may sell its $2B women's health unit

As Pfizer attempts to shift its focus toward developing treatments with higher returns, the U.S. pharma giant is weighing the sale of its women's health division, which is valued at about $2 billion, according to Bloomberg.

The drugmaker is currently gauging interest from potential buyers. The women's health division may draw bids from both private equity firms and rival pharma companies, people familiar with the matter told the publication.

Pfizer's women's health unit includes products such as menopause treatments Premarin, Prempro and Premphase.

By selling off the unit, Pfizer would become the latest drugmaker to sell its women's health lines as it shifts resources to other parts of its portfolio.  Both Allergan and Teva Pharmaceuticals have announced plans to wind down their women's health units.

Read the full report here.

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars